Niramai

For physicians, Niramai's Thermalytix platform represents a significant step forward in adjunctive breast cancer screening. Its core value lies in its US FDA clearance and CE marking, providing regulatory validation for its use as an adjunct imaging test. The technology is non-invasive and radiation-free, addressing patient concerns and making it suitable for frequent screening without health risks. Crucially, it is effective for women of all ages (18-80+) and is not compromised by breast density, a known limitation of mammography. This makes it a vital tool for screening younger women or those with dense breast tissue. Proof of its efficacy is substantial, with support from 39 patents and over 55 clinically reviewed publications. The system has already been used to screen over 300,000 women across 22+ countries. Its portability allows you to extend screening services beyond the hospital, into primary care clinics or community health camps. Financially, the vendor claims the equipment and operating expenses are 10-20% of traditional methods, offering a cost-effective way to expand diagnostic capabilities.